Biocompatible Nanoparticle Technology Being Used to Develop Cancer Therapies & Rapid Diagnostics
Sona’s unique gold nanorods have the potential to power the next generation of lateral flow diagnostics and play a key role in the advancement of impactful scientific and medical applications
Available for Mac, Windows, Chrome, and iOS.
Trusted by global brands
Previous
Next
Technology
Sona Gold Nanorod ("GNR") Technology
Uniquely biocompatible.
Unlocking of in-vivo medical applications potential
Applications
Targeted Hyperthermia Therapy
Sona GNRs in targeted hyperthermia may create the
opportunity to treat cancer without doing significant harm to healthy cells.
Concussion Tests
Sona’s concussion screening test to be used at the scene of injury
Bovine Tuberculosis Tests
Early detection at low cost without the need for test-and-slaughter
Latest News Releases
- November 27, 2023
Sona Nanotech Closes Private Placement Financing to Raise $750,000 in Gross Proceeds and Announces Additional Financing
Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”) is pleased to announce that it has closed its private placement that was announced on October 18, 2023 with the issuance of 3,750,000 shares at $0.20 per share and 1,875,000 common share purchase warrants exercisable to purchase an additional common share of Sona at a price of $0.30 per share until November 24, 2025.
- October 18, 2023
- October 11, 2023
Market Coverage Report
Report by:
Dated:
Varius nisi aliquet at nisi augue tempus. Eu vitae maecenas tellus varius quis pretium. Amet nibh venenatis nunc feugiat lectus.
Insights, Events and Media
Enim, justo, sed etiam lacus, nibh pellentesque ante sem vulputate. At etiam cursus adipiscing viverra dui.